

IJP 03081

## Research Papers

# QSARs of some novel antibacterial benzimidazoles, benzoxazoles, and oxazolopyridines against an enteric gram-negative rod; *K. pneumoniae*

Ismail Yalçın and Esin Şener

Ankara University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, 06100 Ankara (Turkey)

(Received 27 April 1992)

(Modified version received 12 October 1992)

(Accepted 13 October 1992)

*Key words:* Benzoxazole; Oxazolo(4,5-*b*)pyridine; Benzimidazole; QSAR; Antibacterial activity; *Klebsiella pneumoniae*

---

### Summary

A set of previously synthesized 2,5-disubstituted benzimidazole (I), benzoxazole (II), and 2-substituted oxazolo(4,5-*b*)pyridine (III) derivatives were tested for in vitro growth inhibitory activity against *K. pneumoniae* and the quantitative structure-activity relationships (QSARs) were analyzed by a computer-assisted multiple regression procedure. The activity contributions for either heterocyclic ring systems or substituent effects were determined from the correlation equations and predictions for the lead optimization were described. The resulting QSAR revealed that the oxazolo(4,5-*b*)pyridine ring system with the substitution of a benzyl moiety at position 2 was the most favorable structure over the other heterocyclic nuclei against *K. pneumoniae*. The position R in the fused ring system was found to be important for improving the activity by substitution at this position by hydrogen accepting groups with the electronic effect of negative field interactions.

---

### Introduction

The development of new and different antimicrobial agents is a very important step and much research effort is directed toward to the design of

available drugs that are resistant to inactivation by bacterial enzymes.

The abundant use of antimicrobial drugs, particularly in hospitalized patients, leads to the suppression of drug-susceptible organisms in the gut flora and favors the persistence and growth of drug resistant bacteria, including *Klebsiella* (Martin, 1982). The closed environment of hospitals favors transmission of these resistant organisms and such microorganisms constitute particularly difficult problems especially in granulopenic and immunocompromised patients (Boyd, 1984).

---

Correspondence to: I. Yalçın, Ankara University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, 06100 Ankara, Turkey.

*K. pneumoniae*, originally known as a respiratory pathogen, is now commonly encountered in hospital infections of the respiratory and urinary tracts. It produces extensive hemorrhagic necrotizing consolidation of the lung, which, if untreated, has a high mortality rate. Occasionally, it produces urinary tract infection or enteritis in children and bacteremia with focal lesions in debilitated patients (Joklik et al., 1980; Jawetz et al., 1984).


Nosocomial (hospital-acquired) infections caused by enteric gram-negative rods are often resistant to antibiotic therapy and have become a serious medical problem. Research has clearly established that multiple resistance among gram-negative organisms to a variety of antibiotics occurs and can be transmitted to previously non-resistant strains of the same species and, indeed, to different species of bacteria (Martin, 1982; Sande and Mandell, 1990).

In the search for new and different antimicrobial agents, a variety of benzimidazole derivatives have previously been investigated with respect to their antimicrobial activities (Islip, 1979; Pedini et al., 1987, 1990). Recent observations suggest that, besides the substituted benzimidazole derivatives, several analogs of this ring system, such as benzoxazole derivatives, also indicate potential antibacterial activity with lower toxicity (Geigy, 1971; Brown et al., 1978; Haugwitz et al., 1982; Hisano et al., 1982; De Meo et al., 1989).

Consequently, in view of these phenomena and the fact that many effective antimicrobial agents bear a heterocyclic system in their molecule (Daidone, 1990), we have synthesized different derivatives of benzoxazoles, benzimidazoles, and oxazolo(4,5-*b*)pyridines during the last few years (Yalçın et al., 1985, 1990; Şener et al., 1987a,b). Our investigations suggest that they have a broad spectrum of antimicrobial activity, especially against gram-negative microorganisms (De Meo et al., 1989; Yalçın et al., 1990).

In this study, the *in vitro* growth inhibitory activity of the previously synthesized compounds, 2,5-disubstituted benzimidazoles (I), benzoxazoles (II) and 2-substituted oxazolo(4,5-*b*)pyridines (III) against *K. pneumoniae* was determined and quantitative structure-activity relation-

ships (QSARs) of these derivatives were analyzed.



I, X: NH Y: CH Z: CH<sub>2</sub> or -

II, X: O Y: CH Z: CH<sub>2</sub> or -

III, X: O Y: N Z: -

The substituents at positions R and R<sub>1</sub>, which are given in Table 1, are electron donating or withdrawing groups. The activity contributions for either the ring systems and/or the substituents have been calculated from the correlation equations and the predictions for the lead optimization have been described by the results obtained from QSAR analysis.

## Materials and Methods

### Data processing


An extrathermodynamic approach in the quantitative analysis of structure-activity relationships (QSAR) has been most widely and effectively used for theoretical drug design. This method has also been called the Hansch approach and it assumes that the potency of a certain biological activity exerted by a series of congeneric compounds can be expressed in terms of a function of various physicochemical (electronic, steric, and hydrophobic) effects, with provision for structural or theoretical effects (Fujita, 1990). This assumption is summarized in Eqn 1:

$$f(\text{biological activity}) = f(\text{electronic}) + f(\text{steric}) \\ + f(\text{hydrophobic}) + [f(\text{structural}) \\ + f(\text{theoretical})] \quad (1)$$

If these functions could be formulated in a equation showing that certain effects are favorable for the activity, the structural modifications which enhance such properties would be expected to generate compounds of potent activity.

TABLE 1

Compounds and parameters used in Eqn 8



Compound	R	R <sub>1</sub>	X	Y	Z	H <sub>ACCEPT,R</sub>	F <sub>R</sub>	I <sub>X</sub>	I <sub>Y</sub>	I <sub>Z</sub>	MIC (μg/ml)	Observed <sup>a</sup>	Calculated <sup>b</sup>	Residual
1	H	H	O	CH	-	0	0.00	0	0	0	12.5	4.1936	4.2445	-0.0509
2	H	OCH <sub>3</sub>	O	CH	-	0	0.00	0	0	0	12.5	4.2557	4.2445	0.0112
3	H	C(CH <sub>3</sub> ) <sub>3</sub>	O	CH	-	0	0.00	0	0	0	12.5	4.3033	4.2445	0.0588
4	H	NH <sub>2</sub>	O	CH	-	0	0.00	0	0	0	12.5	4.2258	4.2445	-0.0187
5	H	NHCH <sub>3</sub>	O	CH	-	0	0.00	0	0	0	12.5	4.2538	4.2445	0.0093
6	Cl	CH <sub>3</sub>	O	CH	-	0	0.41	0	0	0	25	3.9889	4.0491	-0.0602
7	Cl	C <sub>2</sub> H <sub>5</sub>	O	CH	-	0	0.41	0	0	0	25	4.0132	4.0491	-0.0359
8	Cl	C(CH <sub>3</sub> ) <sub>3</sub>	O	CH	-	0	0.41	0	0	0	25	4.0580	4.0491	0.0089
9	Cl	NHCOCH <sub>3</sub>	O	CH	-	0	0.41	0	0	0	25	4.0595	4.0491	0.0104
10	Cl	NHCH <sub>3</sub>	O	CH	-	0	0.41	0	0	0	25	4.0148	4.0.191	-0.0343
11	Cl	Cl	O	CH	-	0	0.41	0	0	0	25	4.0238	4.0.191	-0.0253
12	Cl	NO <sub>2</sub>	O	CH	-	0	0.41	0	0	0	25	4.0624	4.0.191	0.0133
13	NO <sub>2</sub>	H	O	CH	-	1	0.67	0	0	0	12.5	4.2837	4.3253	-0.0416
14	NO <sub>2</sub>	CH <sub>3</sub>	O	CH	-	1	0.67	0	0	0	12.5	4.3083	4.3253	-0.0170
15	NO <sub>2</sub>	C(CH <sub>3</sub> ) <sub>3</sub>	O	CH	-	1	0.67	0	0	0	12.5	4.37.18	4.3253	0.0495
16	NO <sub>2</sub>	NH <sub>2</sub>	O	CH	-	1	0.67	0	0	0	12.5	4.3100	4.3253	-0.0153
17	NO <sub>2</sub>	Cl	O	CH	-	1	0.67	0	0	0	12.5	4.3418	4.3253	0.0165
18	NO <sub>2</sub>	Br	O	CH	-	1	0.67	0	0	0	12.5	4.4070	4.3253	0.0817
19	NH <sub>2</sub>	H	O	CH	-	1	0.02	0	0	0	6.25	4.5269	4.6351	-0.1082
20	NH <sub>2</sub>	C <sub>2</sub> H <sub>5</sub>	O	CH	-	1	0.02	0	0	0	6.25	4.6060	4.6351	-0.0291
21	NH <sub>2</sub>	NO <sub>2</sub>	O	CH	-	1	0.02	0	0	0	6.25	4.6142	4.6351	-0.0209
22	NH <sub>2</sub>	Br	O	CH	-	1	0.02	0	0	0	6.25	4.7197	4.6351	0.0846
23	NH <sub>2</sub>	F	O	CH	-	1	0.02	0	0	0	6.25	4.6296	4.6351	-0.0055
24	NH <sub>2</sub>	N(CH <sub>3</sub> ) <sub>2</sub>	O	CH	-	1	0.02	0	0	0	6.25	4.6313	4.6351	-0.0038
25	CH <sub>3</sub>	CH <sub>3</sub>	O	CH	-	0	-0.04	0	0	0	12.5	4.2519	4.2636	-0.0117
26	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	O	CH	-	0	-0.04	0	0	0	12.5	4.2783	4.2636	0.0147
27	CH <sub>3</sub>	OCH <sub>3</sub>	O	CH	-	0	-0.04	0	0	0	12.5	4.2819	4.2636	0.0183
28	CH <sub>3</sub>	F	O	CH	-	0	-0.04	0	0	0	12.5	4.2595	4.2636	-0.0041
29	CH <sub>3</sub>	NHCOCH <sub>3</sub>	O	CH	-	0	-0.04	0	0	0	12.5	4.2874	4.2636	0.0238
30	CH <sub>3</sub>	NHCH <sub>3</sub>	O	CH	-	0	-0.04	0	0	0	12.5	4.2801	4.2636	0.0165
31	CH <sub>3</sub>	N(CH <sub>3</sub> ) <sub>2</sub>	O	CH	-	0	-0.04	0	0	0	12.5	4.3050	4.2636	0.0414
32	H	CH <sub>3</sub>	O	N	-	0	0.00	0	1	0	6.25	4.5298	4.5763	-0.0465
33	H	C <sub>2</sub> H <sub>5</sub>	O	N	-	0	0.00	0	1	0	6.25	4.5584	4.5763	-0.0179
34	H	C(CH <sub>3</sub> ) <sub>3</sub>	O	N	-	0	0.00	0	1	0	6.25	4.6090	4.5763	0.0327
35	H	OCH <sub>3</sub>	O	N	-	0	0.00	0	1	0	6.25	4.5622	4.5763	-0.0141
36	H	OC <sub>2</sub> H <sub>5</sub>	O	N	-	0	0.00	0	1	0	6.25	4.5883	4.5763	0.0120
37	H	NH <sub>2</sub>	O	N	-	0	0.00	0	1	0	6.25	4.5319	4.5763	-0.0444
38	H	NO <sub>2</sub>	O	N	-	0	0.00	0	1	0	6.25	4.5900	4.5763	0.0137
39	H	Cl	O	N	-	0	0.00	0	1	0	6.25	4.5703	4.5763	-0.0060
40	H	Br	O	N	-	0	0.00	0	1	0	6.25	4.6471	4.5763	0.0708
41	H	H	O	CH	CH <sub>2</sub>	0	0.00	0	0	1	6.25	4.5282	4.5918	-0.0636
42	H	OCH <sub>3</sub>	O	CH	CH <sub>2</sub>	0	0.00	0	0	1	6.25	4.5865	4.5918	-0.0053
43	H	Br	O	CH	CH <sub>2</sub>	0	0.00	0	0	1	6.25	4.6672	4.5918	0.0754
44	H	Cl	O	CH	CH <sub>2</sub>	0	0.00	0	0	1	6.25	4.5945	4.5918	0.0027
45	H	NO <sub>2</sub>	O	CH	CH <sub>2</sub>	0	0.00	0	0	1	6.25	4.6129	4.5918	0.0211
46	NO <sub>2</sub>	H	O	CH	CH <sub>2</sub>	1	0.67	0	0	1	6.25	4.6130	4.6725	-0.0595
47	NO <sub>2</sub>	OCH <sub>3</sub>	O	CH	CH <sub>2</sub>	1	0.67	0	0	1	6.25	4.6610	4.6725	-0.0115
48	NO <sub>2</sub>	Br	O	CH	CH <sub>2</sub>	1	0.67	0	0	1	6.25	4.7300	4.625	0.05-5

(continued overleaf)

TABLE 1 (continued)

Com- pound	R	R <sub>1</sub>	X	Y	Z	H <sub>ACCEPT,R</sub>	F <sub>R</sub>	I <sub>X</sub>	I <sub>Y</sub>	I <sub>Z</sub>	MIC (μg/ml)	Observed <sup>a</sup>	Calculated <sup>b</sup>	Residual
49	NO <sub>2</sub>	Cl	O	CH	CH <sub>2</sub>	1	0.67	0	0	1	6.25	4.6680	4.6725	-0.0045
50	NO <sub>2</sub>	NO <sub>2</sub>	O	CH	CH <sub>2</sub>	1	0.67	0	0	1	6.25	4.6840	4.6725	0.0115
51	NO <sub>2</sub>	NO <sub>2</sub>	NH	CH	CH <sub>2</sub>	1	0.67	1	0	1	12.5	4.373	4.3641	0.0132
52	NO <sub>2</sub>	OCH <sub>3</sub>	NH	CH	CH <sub>2</sub>	1	0.67	1	0	1	12.5	4.3549	4.3641	-0.0092
53	NO <sub>2</sub>	OC <sub>2</sub> H <sub>5</sub>	NH	CH	CH <sub>2</sub>	1	0.67	1	0	1	12.5	4.3i59	4.3641	0.0118
54	CH <sub>3</sub>	CH <sub>3</sub>	NH	CH	CH <sub>2</sub>	0	-0.04	1	0	1	12.5	4.2760	4.3023	-0.0263
55	CH <sub>3</sub>	OCH <sub>3</sub>	NH	CH	CH <sub>2</sub>	0	-0.04	1	0	1	12.5	4.3045	4.3023	0.0022
56	CH <sub>3</sub>	OC <sub>2</sub> H <sub>5</sub>	NH	CH	CH <sub>2</sub>	0	-0.04	1	0	1	12.5	4.2869	4.3023	-0.0154
57	H	CH <sub>3</sub>	NH	CH	-	0	0.00	1	0	0	25	3.9201	3.9361	0.0160
58	H	OCH <sub>3</sub>	NH	CH	-	0	0.00	1	0	0	25	3.9523	3.9361	0.0162
59	CH <sub>3</sub>	OCH <sub>3</sub>	NH	CH	-	0	-0.04	1	0	0	25	3.9786	3.9551	0.0235

<sup>a</sup> Defined as  $\log 1/C$ .

<sup>b</sup> Using Eqn 8.

Multiple regression analysis which involves finding the best fit of a dependent variable (microbiological activity) to a linear combination of independent variables (descriptors) by the least squares method was used (Chu, 1980). This is formally expressed as follows;

$$y = a_0 + a_1x_1 + a_2x_2 + \dots + a_nx_n + \epsilon \quad (2)$$

where  $y$  is related to the microbiological activity of a compound,  $x_1, x_2, \dots, x_n$  are the descriptor values which are related to the activity, and  $a_0, a_1, a_2, \dots, a_n$  are the regression coefficients determined by the least square analysis, whereas  $\epsilon$  represents the residues. This equation is developed for each compound in our QSAR study.

For the procedure of descriptor selection related to the activity among the candidate set of variables, forward step-wise multiple regression of elimination technique is applied. During the development of the best fit model of the correlation equation, the minimum  $F$  value for entering and removing the variables in the step-wise multiple regression was taken as 8.0 which is statistically significant at the 1% level of probability (Şener et al., 1991).

In order to judge the validity of the predictive power of the QSAR, the cross-validation method is also applied to the original data set by remov-

ing a group of compounds from the data in such a way that each observation (compound) is deleted once and once only. For each reduced data set a model is developed and the response values of the deleted observations are predicted from this model and finally the resulting PRESS (predictive residual sum of squares) is calculated via the closed form given in Eqn 3 (Rawlings, 1988; Wold, 1991):

$$\text{PRESS} = \sum_i \left[ (y_i - \hat{y}_i)^2 / (1 - h_{ii})^2 \right] \quad (3)$$

where  $y_i$  and  $\hat{y}_i$  are the response (activity) values of observation  $i$  ( $i = 1, 2, \dots, n$ ), observed and calculated by the best equation, respectively. The diagonal elements of the 'hat' matrix are denoted by  $h_{ii}$  in the equation and calculated by the computer program used in this QSAR study (Rawlings, 1988).

Regression analysis and calculations were run on an IBM 360/158 computer using the BMDP 2R statistical program package. Graphics were obtained from the STATGRAPHICS software. In equations, the figures in parentheses are the standard errors of the regression coefficients. For a given equation,  $n$  is the number of compounds,  $R^2$  denotes the square of the multiple correlation

coefficients,  $F$  is the significance test and  $s$  represents the residual standard deviation.

#### Determination of parameters

A congeneric set of 2,5-disubstituted benzimidazoles, benzoxazoles, and 2-substituted oxazolo (4,5-*b*)pyridine derivatives 1–59 were considered for this study.

The candidate set of variables used in this analysis are hydrophobic, electronic, steric and structural parameters. The structural variable  $I_Y$  expresses the replacement of  $-\text{CH}=\text{}$  by the isosteric group of  $-\text{N}=\text{}$  in the six-membered ring of the fused ring system.  $I_Y$  is defined as 0 for type I and II compounds and 1 for type III compounds. The other structural variable  $I_X$  expresses the exchange between  $-\text{O}-$  and  $-\text{NH}-$  groups in the five-membered ring and is represented as 1 for type I, and 0 for type II and III compounds. Additionally,  $I_Z$  has a value of 1 for the presence of a methylene group and 0 for its absence between the *p*-substituted phenyl moiety and the fused ring system in position 2. The hydrogen donating/accepting capabilities ( $H_{\text{DONOR}}/H_{\text{ACCEPT}}$ ) of the substituents at R and R<sub>1</sub> are the indicator variables.

The screened physicochemical parameters in this QSAR study are  $\pi$  for the hydrophobic effects,  $F$  (field effect),  $R$  (resonance effect) as the electronic influence and MR, Verloop's STERIMOL parameters ( $L$ ,  $B_1$ ,  $B_4$ ) for the steric interactions of the substituents R and R<sub>1</sub>. Values for

all candidate physicochemical variables used in this QSAR study were taken from the table of Hansch and Leo (1979). The values of the descriptors related to the activity among the candidate set of variables of the best equation (Eqn 8) in the QSAR analysis are shown in Table 1.

#### In vitro microbiological activity

The antibacterial activities against the strain *K. pneumoniae* NTCC 52211 were determined as the minimum inhibitory concentration (MIC) values in vitro by a 2-fold serial dilution technique (Charles et al., 1979; Shadomy and Espinel, 1980). The test was performed using the compounds which were dissolved in absolute ethanol (0.4 mg/ml) and further control dilutions in the test medium were furnished at the required quantities of 200, 100, 50, 25, 12.5, 6.25, 3.12, and 1.56  $\mu\text{g}/\text{ml}$  concentrations. In order to ensure that the solvent per se had no effect on bacterial growth, a control test was also performed containing inoculated broth supplemented with only ethanol at the same dilutions used in our experiments and found to be inactive in culture medium. For the antibacterial assay, the cultures were obtained in Mueller Hinton broth (Difco) after 24 h of incubation at  $37 \pm 1^\circ\text{C}$ . Testing was carried out in Mueller Hinton broth at pH 7.4 and the 2-fold serial dilution technique was applied. A set of tubes containing only inoculated broth was kept as controls. After incubation for 24 h at  $37 \pm 1^\circ\text{C}$ , the last tube with no growth of the

TABLE 2

Stepwise development of Eqn 8

Eqn no.	Equation	$n$	$R^2$	$s$	$F$
4	$\log 1/C = 0.196(\pm 0.058)H_{\text{ACCEPT,R}} + 4.315$	59	0.17	0.21	11
5	$\log 1/C = 0.274(\pm 0.051)H_{\text{ACCEPT,R}} + 0.340(\pm 0.067)I_Y + 4.237$	59	0.43	0.18	21
6	$\log 1/C = 0.245(\pm 0.043)H_{\text{ACCEPT,R}} + 0.398(\pm 0.058)I_Y + 0.219(\pm 0.046)I_Z + 4.178$	59	0.60	0.15	27
7	$\log 1/C = 0.415(\pm 0.042)H_{\text{ACCEPT,R}} + 0.371(\pm 0.044)I_Y + 0.252(\pm 0.035)I_Z - 0.443(\pm 0.068)F_R + 4.205$	59	0.77	0.11	46
8	$\log 1/C = 0.400(\pm 0.015)H_{\text{ACCEPT,R}} + 0.332(\pm 0.015)I_Y + 0.347(\pm 0.013)I_Z - 0.477(\pm 0.024)F_R - 0.308(\pm 0.015)I_X + 4.245$	59	0.97	0.04	393 $p < 0.001$




Fig. 1. Plot of the observed vs predicted values ( $\log 1/C$ ) of the in vitro growth inhibitory activity of the compounds against *K. pneumoniae* using Eqn 8.

microorganism was recorded to represent MIC expressed in  $\mu\text{g/ml}$ . The potency has been defined as  $\log 1/C$  in the QSAR analysis where  $C$  is the molar MIC value of the compounds. MIC and the observed  $\log 1/C$  values of the compounds are listed in Table 1.

## Results and Discussion

QSAR analysis reveals that Eqn 8, given in Table 2, represents the best fit equation for the

TABLE 3

Complete analysis of variance table of Eqn 8

Source	Degrees of freedom	Sum of squares	Mean square	F ratio	p level
Total (corrected)	58	3.0335			
Regression	5	2.9538	0.5908		
$H_{\text{ACCEPT,R}}$	1	1.2346	1.2346	821	0.000
$I_Y/H_{\text{ACCEPT,R}}$	1	0.4031	0.4031	268	0.000
$I_Z/H_{\text{ACCEPT,R}}, I_Y$	1	0.6957	0.6957	462	0.000
$F_R/H_{\text{ACCEPT,R}}, I_Y, I_Z$	1	0.0156	0.0156	10	0.002
$I_X/H_{\text{ACCEPT,R}}, I_Y, I_Z, F_R$	1	0.6049	0.6049	402	0.000
Error	53	0.0797	0.0015		

TABLE 4

Correlation matrix of variables used in Eqn 8

	$\log 1/C$	$H_{\text{ACCEPT,R}}$	$I_X$	$I_Y$	$I_Z$	$F_R$
$\log 1/C$	1.00					
$H_{\text{ACCEPT,R}}$	0.41	1.00				
$I_X$	-0.33	-0.01	1.00			
$I_Y$	0.36	-0.30	-0.18	1.00		
$I_Z$	0.37	0.21	0.38	-0.26	1.00	
$F_R$	-0.04	0.67	-0.01	-0.29	0.26	1.00

predictions according to the applied regression analysis and validation test results.

As can be deduced from Fig. 1, the goodness of fit of Eqn 8 is significant, possessing a high  $R^2$  (97%) and a small  $s$  (0.04) with an overall  $F$  test value of 393 at the significant level of  $p < 0.001$ . However, the complete analysis of the variance table of Eqn 8 is also given in Table 3 for further information.

In order to avoid the risk of chance correlation, some circumstances which were pointed out by Topliss and Edwards (1979) and Wold (1991) have been taken into consideration in the study. Thus, 59 observations (compounds) are used to screen the 22 variables for keeping the probability of encountering a chance correlation with  $R^2 \geq 0.9$  at the 1% level or less (Topliss and Edwards, 1979). The search of the simple correlation coefficients which are given in Table 4 also reveals that there is no colinearity between the independent variables in any case.

To prove the predictive power of Eqn 8, cross-validation is applied to the original data set and the resulting PRESS is calculated. The calculated overall PRESS is 0.0996, which is found to

be smaller than the value of SSY (sum of the squares of the response values of the total observations,  $SSY = 3.0335$ ; see Table 3). This proves that the developed model (Eqn 8) predicts better than chance and can be considered statistically significant (Rawlings, 1988; Wold, 1991).

The ratio  $PRESS/SSY$ , which is the approximate confidence interval for predictions of new compounds, is 0.0328 and it also provides proof that the model is valid (Wold, 1991).

In QSAR analysis, Eqn 8 reveals that position R of the fused ring system is important for the antibacterial activity against *K. pneumoniae*. The hydrogen accepting property of a substituent at this position ( $H_{ACCEPT,R}$ ) produces an additive contribution to the activity.

When the physicochemical properties of the substituents are compared, the fitted model indicates that electronic influences of negative field effects at R ( $F_R$ ) enhance the potency.

In addition to this feature, Eqn 8 reveals that the structural parameters  $I_X$ ,  $I_Y$ , and  $I_Z$  are also

significant for the activity. As can be deduced from Fig. 2, the compounds possessing a methylene group between the *p*-substituted phenyl moiety and the fused ring system in position 2 ( $I_Z$ ) are important and provide an improvement in the activity (see compounds 41–50 in Fig. 2). Additionally, activity contributions of the other structural parameters  $I_X$  and  $I_Y$  indicate that the oxazolo(4,5-*b*)pyridine ring system is the preferred structure over the other heterocyclic nuclei against *K. pneumoniae*.

On the other hand, it was observed that there was no statistical significant relationships between the activity and any parameters related to  $R_1$  and the *para* substitution of the phenyl or benzyl moiety has a negligible effect on the activity.

## Conclusion

According to the predictions obtained from QSAR analysis, the lead optimization in this set of compounds can be defined as follows.

The model indicates that the lead compound for the activity against *K. pneumoniae* has the heterocyclic structure of an oxazolo(4,5-*b*)pyridine ring system with the substitution of a benzyl moiety at position 2.

A substituent which possesses hydrogen accepting capability at R improves the activity via the physicochemical property of the electronic effect of negative field interactions.

## References

- Boyd, R.F., *General Microbiology*, Times Mirror/Mosby, Missouri, 1984, pp. 732–749.
- Brown, D.J., Dunlap, W.C., Grigg, G.W. and Danckwerts, L., Purine analogues as amplifiers of phleomycin III. Some 2-alkylthio derivatives of imidazole, benzimidazole, benzoxazole and benzothiazole. *Aust. J. Chem.*, 31 (1978) 447–450.
- Charles, E.S., Agrawal, V.K., Sharma, S., Iyer, R.N., Sarivastava, O.P., Synthesis of 2,5-disubstituted benzimidazoles as potential antihookworm and antimicrobial agents. *Eur. J. Med. Chem. Chim. Ther.*, 14 (1979) 435–438.
- Chu, K.C., The quantitative analysis of structure-activity relationships. In Wolff, M.E. (Ed.), *Burger's Medicinal Chemistry*, Part I, 4th Edn, Wiley, New York, 1980, pp. 393–419.




Fig. 2. Plot of the calculated and observed values ( $\log 1/C$ ) vs index of the compounds (1–59) with 99% intervals of the confidence limits for predictions using Eqn 8.

- Daidone, G., Maggio, B. and Schillaci, D., Salicylanilide and its heterocyclic analogues. A comparative study of their antimicrobial activity. *Pharmazie*, 45 (1990) 441–442.
- De Meo, G., Pedini, M., Ricci, A., Bastianini, L., Sposini, T. and Jacquignon, P., New heterocyclic derivatives with germicidal activity: IV. Synthesis and activity of new 2-(2'-furyl and 2'-thienyl)benzoxazoles with different substituents in the positions 5 and 5'. *Il Farmaco*, 44 (1989) 475–482.
- Fujita, T., The extrathermodynamic approach to drug design. In Ramsden, C.E. (Ed.), *Comprehensive Medicinal Chemistry; The Rational Design, Mechanistic Study & Therapeutic Applications of Chemical Compounds*, Vol. 4, Pergamon, Oxford, 1990, pp. 497–561.
- Geigy Chemical Corp., *US Patent Office* 3,586,670 (1971).
- Hansch, C. and Leo, A., *Substituent Constants for Correlation Analysis in Chemistry and Biology*, Wiley, New York, 1979, p. 65.
- Haugwitz, R.D., Angel, R.G., Jacobs, G.A., Maurer, B.V., Narayanan, V.L., Cruthers, L.R. and Szanto, J., Antiparasitic agents. Synthesis and antihelmintic activities of novel 2-heteroaromatic-substituted isothiocyanatobenzoxazoles and benzothiazoles. *J. Med. Chem.*, 25 (1982) 969–974.
- Hisano, T., Ichikawa, M., Tsumoto, K. and Tasaki, M., Synthesis of benzoxazoles, benzothiazoles and benzimidazoles and evaluation of their antifungal, insecticidal and herbicidal activities. *Chem. Pharm. Bull.*, 30 (1982) 2996–3004.
- Islip, P.J., Anthelmintic agents. In Wolff, M.E. (Ed.), *Burger's Medicinal Chemistry*, Part II, 4th Edn, Wiley, New York, 1979, pp. 481–530.
- Jawetz, E., Melnick, J.L. and Adelberg, E.A., *Review of Medical Microbiology*, 16th Edn, Lange Medical, CA, 1984, pp. 235–251.
- Joklik, W.K., Willett, H.P. and Amos, D.B., *Zinsser Microbiology*, 17th Edn, Appleton-Century-Crofts, New York, 1980, pp. 726–736.
- Martin, A.R., Antibiotics. In Doerge, R.F. (Ed.), *Wilson and Giswold's Textbook of Organic Medicinal and Pharmaceutical Chemistry*, 8th Edn, J.B. Lippincott, Philadelphia, 1982, pp. 225–294.
- Pedini, M., Bistocchi, G.A., De Meo, G., Ricci, A., Jacquignon, P., Riccardi, C., Bastianini, L. and Sposini, T., New heterocyclic derivatives of benzimidazole with germicidal activity. *Il Farmaco Ed. Sci.*, 42 (1987) 541–547.
- Pedini, M., De Meo, G., Ricci, A., Bastianini, L. and Jacquignon, P., New heterocyclic derivatives of benzimidazole with germicidal activity: VII. 2-(5'-Nitro-2'-furyl or 2'-thienyl) benzimidazoles with different substituents in the 5-position. *Il Farmaco*, 45 (1990) 303–312.
- Rawlings, J.O., *Applied Regression Analysis*, Wadsworth & Brooks/Cole, Pacific Grove, CA, 1988, pp. 186–189.
- Sande, M.A. and Mandell, G.L., Antimicrobial agents. In Gilman, A.G., Rall, T.W., Nies, A.S. and Taylor, P. (Eds), *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, 8th Edn, Pergamon, New York, 1990, pp. 1098–1116.
- Şener, E., Yalçın, İ., Özden, S., Özden, T., Akin, A. and Yıldız, S., Synthesis and microbiological activities of 5-amino-2-(*p*-substituted phenyl)benzoxazole derivatives. *DOGA TU J. Med. Chem.*, 11 (1987a) 391–396.
- Şener, E., Yalçın, İ., Akin, A. and Noyanalpan, N., Antifungal activity of 2-benzylbenzoxazole derivatives and QSARs by Free-Wilson analysis. *J. Fac. Pharm. Gazi*, 4 (1987b) 1–9.
- Şener, E., Yalçın, İ. and Sungur, E., QSAR of some antifungal benzoxazoles and oxazolo(4,5-*b*)pyridines against *C. albicans*. *Quant. Struct.-Act. Relat.*, 10 (1991) 223–228.
- Shadomy, S. and Espinel A., *Manual of Clinical Microbiology*, Am. Soc. Microbiol., Washington, DC, 1980, p. 647.
- Topliss, J.G. and Edwards, R.P., Chance factors in studies of quantitative structure-activity relationships. *J. Med. Chem.*, 22 (1979) 1238–1244.
- Wold, S., Validation of QSARs. *Quant. Struct.-Act. Relat.*, 10 (1991) 191–193.
- Yalçın, İ., Şener, E. and Özden, T., Synthesis and structure elucidations of 2-(*p*-substituted phenyl)oxazolo(4,5-*b*)pyridine derivatives. *J. Fac. Pharm. Ankara*, 15 (1985) 69–78.
- Yalçın, İ., Şener, E., Özden, T., Özden, S. and Akin, A., Synthesis and microbiological activity of 5-methyl-2-(*p*-substituted phenyl)benzoxazoles. *Eur. J. Med. Chem.*, 25 (1990) 705–708.